Search Results - "Salvador Bofill, Francisco Javier"

Assessment of Prognostic and Therapeutic Factors in Male Breast Cancer: An Observational Study of a Southwest Spanish Single Center by Herrero, Daniel, Morales Herrero, María Rocío, López Guerra, José Luis, Camacho-Mejías, Alberto Sánchez, García, Irene Carrasco, Fernández, Paloma Santos, Almeida González, Carmen Victoria, Viñuales, Marta Benavent, González, Alejandro Falcón, Periáñez, Álvaro Montaño, Mancha, Rosario González, Salvador Bofill, Francisco Javier, Borrego, Manuel Ruiz

“…Background: Male breast cancer (MBC) accounts for less than 1% of breast cancer, requiring extrapolation of results from studies in women. The aim of the study…”
Get full text

Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response by Brasó-Maristany, Fara, Ferrero-Cafiero, Juan Manuel, Falato, Claudette, Martínez-Sáez, Olga, Cejalvo, Juan Miguel, Margelí, Mireia, Tolosa, Pablo, Salvador-Bofill, Francisco Javier, Cruz, Josefina, González-Farré, Blanca, Sanfeliu, Esther, Òdena, Andreu, Serra, Violeta, Pardo, Francisco, Luna Barrera, Ana María, Arumi, Miriam, Guerra, Juan Antonio, Villacampa, Guillermo, Sánchez-Bayona, Rodrigo, Ciruelos, Eva, Espinosa-Bravo, Martín, Izarzugaza, Yann, Galván, Patricia, Matito, Judith, Pernas, Sonia, Vidal, Maria, Santhanagopal, Anu, Sellami, Dalila, Esker, Stephen, Fan, Pang-Dian, Suto, Fumitaka, Vivancos, Ana, Pascual, Tomás, Prat, Aleix, Oliveira, Mafalda

“…Patritumab deruxtecan (HER3-DXd) exhibits promising efficacy in breast cancer, with its activity not directly correlated to baseline ERBB3 /HER3 levels. This…”
Get full text

A Cross-Sectional Validation Study of Camry EH101 versus JAMAR Plus Handheld Dynamometers in Colorectal Cancer Patients and Their Correlations with Bioelectrical Impedance and Nutritional Status by Jiménez-Sánchez, Andrés, Pereira-Cunill, José Luis, Limón-Mirón, María Luisa, López-Ladrón, Amelia, Salvador-Bofill, Francisco Javier, García-Luna, Pedro Pablo

“…Reduced muscle strength (dynapenia) and mass (atrophy) are prognostic factors in oncology. Measuring maximal handgrip strength with dynamometers is feasible…”
Get full text

Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study by Alés-Martínez, José Enrique, Balmaña, Judith, Sánchez-Rovira, Pedro, Salvador Bofill, Francisco Javier, García Sáenz, Jose Ángel, Pimentel, Isabel, Morales, Serafín, Fernández-Abad, María, Lahuerta Martínez, Ainhara, Ferrer, Neus, Zamora, Pilar, Bermejo, Begoña, Díaz-Redondo, Tamara, López-Ceballos, María Helena, Galán, María, Pérez-Escuredo, Jhudit, Calabuig, Laura, Sampayo, Miguel, Pérez-Garcia, José Manuel, Cortés, Javier, Llombart-Cussac, Antonio

“…To evaluate the efficacy and safety of the combination of olaparib plus trastuzumab in patients with HER2-positive advanced breast cancer (ABC) and germinal…”
Get full text

SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer by Pascual, Tomás, Oliveira, Mafalda, Ciruelos, Eva, Bellet Ezquerra, Meritxell, Saura, Cristina, Gavilá, Joaquin, Pernas, Sonia, Muñoz, Montserrat, Vidal, Maria J, Margelí Vila, Mireia, Cejalvo, Juan M, González-Farré, Blanca, Espinosa-Bravo, Martin, Cruz, Josefina, Salvador-Bofill, Francisco Javier, Guerra, Juan Antonio, Luna Barrera, Ana María, Arumi de Dios, Miriam, Esker, Stephen, Fan, Pang-Dian, Martínez-Sáez, Olga, Villacampa, Guillermo, Paré, Laia, Ferrero-Cafiero, Juan M, Villagrasa, Patricia, Prat, Aleix

“…Preclinical data support a key role for the human epidermal growth factor receptor 3 (HER3) pathway in hormone receptor (HR)-positive breast cancer. Recently,…”
Get full text

Abstract P2-26-17: Establishment of an in vitro preclinical platform: A living biobank of patient-derived organoids with ER+ breast cancer by Dominguez-Cejudo, Maria A, Chapresto, Raquel, Gil-Torralvo, Ana, Bofill, Francisco Javier Salvador, Molina-Pinelo, Sonia

“…Introduction and objectives Estrogen receptor positive (ER+) tumors are the most common form of breast cancer and are responsible for most of the deaths from…”
Get full text

Abstract PD13-04: Activity of patritumab deruxtecan, a HER3-directed antibody drug conjugate, in early breast cancer according to ERBB3 expression: Interim analysis results of a window-of-opportunity study (SOLTI-1805 TOT-HER3) by Prat, Aleix, Cejalvo, Juan M., Pare, Laia, Martínez-Sáez, Olga, Vila, Mireia Margelí, Falato, Claudette, Cruz, Josefina, de Dios, Miriam Arumí, Vidal, Maria J, Guerra, Juan Antonio, Barrera, Ana Maria Luna, Tolosa, Pablo, Salvador-Bofill, Francisco Javier, Pernas, Sonia, Gonzáles-Farré, Blanca, Sanfeliu, Esther, Ciruelos, Eva, Serra, Violeta, Espinosa-Bravo, Martin, Izarzugaza, Yann, Esker, Stephen, Fan, Pang-Dian, Villacampa, Guillermo, Ferrero-Cafiero, Juan M, Pascual, Tomás, Oliveira, Mafalda

“…Introduction Patritumab deruxtecan (U3-1402; HER3-DXd) is a HER3-directed antibody drug conjugate with demonstrated clinically meaningful antitumor activity…”
Get full text

Abstract PO1-27-07: Is HER2-low a biologically distinct breast cancer (BC) subtype? Prognosis and pathological complete response rate after neoadjuvant treatment (NAT) in early breast cancer (BC) HER2 negative by Gil-Torralvo, Ana, Rodriguez, Yeray, Falcon, Alejandro, Morales, David, Cejuela, Mónica, Miras, Isabel, Amérigo, Marta, Ruíz - Borrego, Manuel, Bayo, Juan, Bofill, Francisco Javier Salvador

“…Background: Overexpression of HER2 is a significant prognostic and predictive factor in early breast cancer. HER2 positive tumors are those scored by…”
Get full text

Abstract P3-01-13: Palbociclib, ribociclib and abemaciclib in real-world data: risk of disease progression on first-line treatment of metastatic breast cancer by Cejuela, Mónica, Castilla, M. ángeles, Benavent, Marta, Molina-Pinelo, Sonia, Dominguez-Cejudo, Maria A, Gil, Ana, Falcon, Alejandro, Bofill, Francisco Javier Salvador

“…Introduction and objectives: Cyclin dependent kinase (CDK) 4/6 inhibitors along with endocrine therapy (ET) is the standard first-line for endocrine receptor…”
Get full text

Abstract PO3-05-06: Targeting PAM50 HER2-Enriched intrinsic subtype with enzalutamide in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer: results of the SOLTI-1502 ARIANNA trial by Oliveira, Mafalda, Pascual, Tomás, Pernas, Sonia, Margelí, Mireia, Blanch, Salvador, Adamo, Barbara, Bofill, Francisco Javier Salvador, Gonzalez-Farré, Xavier, Chillara, Samyukta, Galván, Patricia, Sanfeliu, Esther, Blasco, Paula, Sirenko, Valeria, Espinosa, Alejandra, Perou, Charles M, Prat, Aleix, Manso, Luis

“…Background Pre-clinical evidence and retrospective studies suggest that PAM50 HER2-Enriched (HER2-E), HR+/HER2- tumors have estrogen receptor (ER) independence…”
Get full text

Abstract P1-04-18: Identification of UGT2B family genes as potential biomarkers of response to neoadjuvant therapy in HER2+ breast cancer by Gil-Torralvo, Ana, Benavent, Marta, Dominguez-Cejudo, Maria A, Falcon, Alejandro, Cejuela, Mónica, Vieites, Begoña, Molina-Pinelo, Sonia, Borrego, Manuel Ruiz, de la Haba-Rodríguez, Juan, Queipo, Maria I, Bofill, Francisco Javier Salvador

“…INTRODUCTION Human Epidermal Growth Factor Receptor (HER2) is overexpressed and/or amplified in 15-20% of breast cancer at time of first diagnosis and is…”
Get full text

Abstract PO3-05-07: SOLTI-1718 NEREA Trial: Neratinib in hormone receptor (HR)-positive/HER2-negative HER2-enriched (HER2-E) advanced breast cancer (BC) by Ciruelos, Eva, Saura, Cristina, Gonzalez-Farré, Xavier, Bofill, Francisco Javier Salvador, Vidal, Maria, Blancas, Isabel, López-Miranda, Elena, Iglesias, Maria, Arumí, Míriam, Margelí, Mireia, Pulido, Catarina, Murillo, Serafin Morales, Henao, Fernando, Sanchez, Pilar, Alves, Sara, Ortiz, Ana Godoy, Coelho, José Passos, Escrivá-de-Romaní, Santiago, Espinosa, Alejandra, Pascual, Tomás, Prat, Aleix

“…Background Breast cancer (BC) is a clinically and biologically heterogenous disease where intrinsic subtypes play a role. Non-luminal subtypes within…”
Get full text

Magnetic Resonance Diffusion as Predictive Value of Response to Treatment with Chemo-Radiotherapy in Patients with Locally Advanced Rectal Cancer by Inmaculada, Gallego Jimenez, Susana, Rico Gala, Amelia, López-Ladrón, Fernández-Parra Eva, M., David, Morales Pancorbo, Javier, Salvador Bofill Francisco

Get full text

Abstract P4-07-29: Olaparib plus Trastuzumab in HER2[+] BRCA-Mutated Advanced Breast Cancer Patients: The OPHELIA Study by Alés-Martínez, José E., Balmaña, Judith, Sánchez-Rovira, Pedro, Bofill, Francisco Javier Salvador, García-Sáenz, José Ángel, Pimentel, Isabel, Murillo, Serafin Morales, Fernández, Adela, Martínez, Ainhara Lahuerta, Ferrer, Neus, Zamora, Pilar, Bermejo, Begoña, Díaz-Redondo, Tamara, Lopez-Ceballos, María Helena, Galán, María, Malfettone, Andrea, Calabuig, Laura, Sampayo-Cordero, Miguel, Pérez-García, José Manuel, Cortés, Javier, Llombart-Cussac, Antonio

“…Background: Olaparib (O) is approved for the treatment of HER2[-] patients (pts) with early or metastatic breast cancer and a germline BRCA mutation…”
Get full text

Abstract P5-02-31: Genetic determinants of response to patritumab deruxtecan (HER3-DXd) in hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer: a correlative analysis from SOLTI TOT-HER3 trial by Brasó-Maristany, Fara, Falato, Claudette, Martínez-Sáez, Olga, Cejalvo, Juan Miguel, Margelí, Mireia, Tolosa, Pablo, Bofill, Francisco Javier Salvador, Cruz, Josefina, González-Farré, Blanca, Sanfeliu, Esther, Arumí, Míriam, Villacampa, Guillermo, Ciruelos, Eva, Espinosa-Bravo, Martín, Izarzuzaga, Yann, Galván, Patricia, Matito, Judit, Pernas, Sonia, Santhanagopal, Anu, Esker, Stephen, Patel, Parul, Fan, Pang-Dian, Ferrero-Cafiero, Juan Manuel, Vivancos, Ana, Pascual, Tomás, Prat, Aleix, Oliveira, Mafalda

“…Background: Baseline HER3 protein or ERBB3 mRNA levels do not seem to predict efficacy from HER3-DXd in early-stage and advanced HR+/HER2- breast cancer (Prat…”
Get full text

Abstract OT2-08-02: SOLTI-1907 ATREZZO: Targeting hormonal receptor negative (HR-) or PAM50 non-luminal disease with atezolizumab in combination with trastuzumab and vinorelbine in HER2-positive metastatic breast cancer (MBC) by Ciruelos, Eva, Perelló, Antonia, González-Santiago, Santiago, López, Ana, Bofill, Francisco Javier Salvador, Albacar, Cinta, Cejalvo, Juan Miguel, Escrivá-de-Romani, Santiago, Blancas, Isabel, Pernas, Sonia, Martínez-Sáez, Olga, Cruz, Josefina, Ponce, Jose, Servitja, Sonia, Perez-Lopez, Maria-Eva, Guerra, Juan A, Sanfeliu, Esther, Rodríguez, Cesar A, Villacampa, Guillermo, Villanueva, Lorea, Tolosa, Pablo, Pascual, Tomás, Prat, Aleix

“…Background Today, there is no clear therapeutic algorithm for patients with metastatic HER2-positive (HER2+) breast cancer (BC) who have progressed to…”
Get full text

Cross-sectional observational study to describe the clinicopathological and biological characteristics and the management of patients with HER2+ metastatic breast cancer who experienced complete or partial remission or disease stabilization during at least 3 years: LongHer study by Zamora, Pilar, Fresno-Vara, Juan Angel, Gámez-Pozo, Angelo, Perez-Carrion, Ramon, Manso, Luis, Crespo Massieu, Carmen, Mendiola, Cesar, Alvarez, Isabel, Margeli Vila, Mireia, Bayo Calero, Juan Lucas, Gonzalez, Xavier, Santaballa, Ana, Ciruelos Gil, Eva Maria, Afonso Gomez, Ruth, Lao Romera, Juan, Catalan, Gustavo, Alvarez Gallego, Jose Valero, Miramon Lopez, Jose, Salvador Bofill, Francisco Javier, Ruiz Borrego, Manuel

“…Abstract only e11081 Background: Trastuzumab has shown an improvement in survival outcomes among patients with HER2+ metastatic breast cancer (MBC)…”
Get full text